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ABSTRACT:  
Juvenile papillomatosis  (JP), the so-called Swiss cheese disease is a rare benign 
breast disease of young adults. An association (up to 28 %) with breast-cancer within 
the family of affected patients has been reported. A multinodular cystic breast-mass 
lesion and calcifications characterizes JP in imaging studies. The histological picture 
is diverse and comprises multiple intraductal-papillomas, usual ductal hyperplasia 
(UDH), ductectasias, perifocal sclerosing adenosis and calcification. Patients with 
complete excision of JP lesions have an excellent follow-up; breast cancer develops 
only on a very low subset of patients. Molecular background of JP has not been 
investigated until now. In this study, we addressed mutational analysis of JP cases 
and correlated these results with follow-up and family-history in context with a 
comprehensive review of JP literature. 
We identified 13 cases fulfilling the criteria of JP. All patients were female with a 
median-age of 38 years (26 to 50 years). Follow-up information was available in 11 of 
13 patients. Sufficient paraffin embedded tissue and good DNA quality for next 
generation sequencing (NGS) was available in 10 patients. Paraffin blocks were 
microdissected in the area of intraductal proliferative disease, the tissue cores 
underwent NGS analysis using Oncomine Comprehensive Panel. 
In 5 of 10 patients, we found PIK3CA mutations, in 2 of 10 patients AKT1 mutations 
in known hotspot regions. Further mutations in MET, FGFR3, PTEN, ATM, NF1 and 
GNAS genes were detected in individual patients. Some of these mutations were 
present at high allelic frequencies suggesting germ line mutations. 2 of 3 patients 
with positive family history had PIK3CA mutation; one patient with positive family 
history had an AKT1 mutation. One patient who subsequently developed invasive 
ductal carcinoma in the contralateral breast possibly had a germ line ATM mutation. 
Our results confirm hotspot mutations in PIK3CA and AKT1 genes in JP associated 
with positive family history for breast cancer, although these mutations are not 
specific for JP. The genetic link between JP, positive family history and subsequent 
risk of breast cancer, needs further studies.  
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INTRODUCTION 
Juvenile papillomatosis (JP) of the breast is a rare histopathological entity occurring 
predominantly in young females (1-3). Usually it presents similarly to fibroadenoma, 
with localized, multinodular mass on breast examination (4). JP lesions are described 
to be firmer and larger than fibroadenomas. Tenderness of lesions can occur. In 
literature, most tumors are described to be located in the upper and lateral quadrant 
of the breast (5). 
Since its first description in 1980, several authors have suggested a correlation 
between positive family history of breast cancer development and juvenile 
papillomatosis (2, 5-7). In 26% to 58% of patients with JP, a family history of breast 
cancer in first- or second-degree relatives has been identified. Positive family history 
together with recurrent bilateral JP have been identified as risk factor for developing 
invasive breast cancer (5, 8). Microscopically, epithelial atypia can be found in JP. 
The grade of epithelial atypia could however not be shown to be associated with 
consecutive development of breast cancer (5-7).  
Until now, there are no data available on molecular alterations in JP and a possible 
genetic link between JP and consecutive breast cancer development.  
Recent studies have explored interactions between AKT1 and PIK3CA signaling 
pathways in benign and/or proliferative breast lesions and confirmed mutual AKT1 
and PIK3CA somatic mutations in non-malignant breast lesions (9-11). The signaling 
pathway of AKT1-PIK3CA plays an important role in normal cell growth, however 
mutations in this pathway are associated with malignant biological features as 
invasion and pathological growth in a subset of malignant tumors and in precursor 
lesions (9-12).  
In this study we therefore addressed the question whether JP and its florid epithelial 
proliferation harbor any hotspot mutations which can be encountered in breast 
cancer and its precancerous stages. We identified a cohort of 13 JP cases, analyzed 
clinicopathological characteristics and performed an Oncomine Comprehensive 
assay on 10 cases.  
 
MATERIALS AND METHODS 
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Patients’ cohort 
We identified thirteen consecutive patients that were diagnosed with JP between 
1997 and 2018 at the Institute of Pathology and Molecular Pathology, University 
Hospital Zurich, Switzerland. Patient data were collected after informed consent had 
been obtained in cases where it was necessary and permission to collect data had 
been given by Ethical Committee of Canton Zurich (KEK-2012 554). The informed 
consent was discussed in details with the patients, who gave permission to use the 
JP samples in a completely anonymous way only for research purposes. As all 
patients have been treated within certified breast centers, the possibility for genetic 
counseling at follow-up consultations is regulated by the institutional guidelines.     
Patient history, family history and gynecological follow up was obtained either by the 
hospital pathology data bank or by contacting primary care providers and 
gynecologists by means of telephone.  Patient data was collected in cooperation with 
Breast Center Zurich Seefeld and the Breast Center at University Hospital of Zurich.   
 
Macroscopic, microscopic and immunohistochemical findings:  
All patients underwent surgical excision; old cases underwent surgery without 
preoperative core- or vacuum biopsies. On gross examination after excision, the 
breast cut surface showed a prominent cystic appearance embedded in fibrotic and 
fatty tissue (Fig. 1, upper image). Microscopically, JP encompassess a large 
spectrum of proliferative findings defined by Rosen et al. in 1980 as: (1) multiple 
intraductal papillomas with or without epithelial atypia, (2) apocrine oder non-
apocrine cysts, (3) extensive intraductal florid hyperplasia, (4) sclerosing adenosis, 
(5) ductal stasis (1). These histological characteristics are illustrated in low power 
view (Fig.1 lower image). 
All excision specimens in our cohort fullfilled the macroscopic and microscopic 
criteria of JP. 
In cases after 2000, additional immunhistochemistry stains were conducted to prove 
the florid epithelial proliferations as usual ductal hyperplasia. These stains included 
basal cytokeratines CK5/6, estrogen receptors (ER) and myoepithelial markes (p63). 
In all cases the usual hyperplasias showed a mosaic staining pattern with basal 
cytokeratin, heterogenous staining pattern with  ER and preservation of myoepithelial 
cell around usual ductal hyperplasia and within the papillary proliferations.  
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Oncomine tumor assay 
Sufficient paraffin embedded tissue or DNA of good quality for next generation 
sequencing (NGS) was available in 10 of 13 patients. Paraffin blocks were punched 
in the area of proliferative disease and tissue cores underwent NGS analysis using 
Oncomine™ Comprehensive Assay v3 (OCAv3, Thermo Fisher Scientific). Sample 
extraction and analysis was performed following manufacturer’s instructions. OCAv3 
is a pan-cancer targeted NGS panel screening for 161 genes, detecting HotSpot 
mutations in 87 genes, covering all exons of 48 genes, detecting Copy Number 
Variations (CNV) in 47 genes and a subset of gene fusions. In this study, only the 
DNA part of the assay (Mutations and CNVs) was performed.  
NGS libraries were sequenced on a S5 (Thermo Fisher Scientific) and the data 
analyzed using Ion Reporter Software 5.10 with default settings (Thermo Fisher 
Scientific). 
 
RESULTS 
Patient characteristics:  
We identified 13 patients diagnosed with JP over the course of 20 years in the 
University Hospital of Zurich, Institute of Pathology and Molecular Pathology. 
Information concerning family history and personal history as well as follow-up could 
be obtained in 11 patients; in two patients, no follow-up data was available. Median 
age at diagnosis was 38 years, ranging from 26 to 50. Median duration of follow up 
was 9 years, ranging from 1 to 17 years.  
Imaging modalities that lead to excision of tumor sample was breast sonography in 3 
patients, breast sonography and mammography in 3 patients, mammography in 1 
patient, mammography and magnetic resonance imaging in 4 patients and breast 
sonography and magnetic resonance imaging (MRI) in one patient.  
11 of 13 patients presented with a palpable mass as the leading clinical symptom, in 
2 of 13 patients there was a suspicious or unclear mammographic finding. 
Histopathologic findings included typical features of JP as described above and 
defined by Rosen et al (1980) (1). In 3 of 13 patients (23%) flat epithelial atypia was 
found.  
In three patients (Nr. 2,9,10), family history was positive for breast malignancy, in all 
cases in second grade relatives. 
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One patient (Nr.5) developed a poorly differentiated invasive ductal breast carcinoma 
on the contralateral breast four years after excision of a JP tumor. This patient died 
due to metastatic disease 2 years later. One additional patient had a recurrence of 
papillomas in the ipsilateral breast.  Patient characteristics are summarized in Table 
1 and Table 2.  
 
Results next generation sequencing:  
In 5 of 10 patients, we found PIK3CA mutations and 2 of 10 patients AKT1 mutations 
in known hotspot regions. Several further mutations in genes such as MET, FGFR3, 
PTEN, ATM, NF1 and GNAS were found in individual patients. The mutations in MET 
and FGFR3 were detected with a variant allele frequency (VAF) of 47.9% and 50.9%, 
respectively, suggestive for a germ-line variant. Moreover, these variants were 
classified in ClinVar with ‘conflicting interpretation of pathogenicity’ and with 
‘benign/likely benign’. All other variants were classified as pathogenic/likely 
pathogenic with two exceptions in the genes PTEN and NF1 where no database 
entry in COSMIC or ClinVar was found. These two variants are predicted to generate 
a loss of function on the protein level, since PTEN exhibits a frame-shift 
(c.44_45delGA,  p.Arg15fs, patient Nr. 6) and NF1 a STOP codon (c.4006C>T, 
p.Gln1336Ter, patient Nr. 5). Interestingly, the NF1 variant was co-mutated with an 
ATM frame-shift mutation with pathogenic classification (ClinVar ID = 186242, patient 
Nr. 5). Another loss of function frame-shift variant was detected in patient Nr. 10 in 
the gene ATM (ClinVar ID = 232841). This variant occurred together with a PIK3CA 
mutation (c.3140A>G, p.His1047Arg) with high VAF of 32%.   
Two of the three patients with positive family history had PIK3CA mutation (patient 
Nr. 2 and Nr. 10); one patient with positive family history had AKT1 mutation in a 
known hotspot region (Nr. 9). The patient (Nr.5) developing contralateral invasive 
metastatic ductal carcinoma in the follow-up period had an ATM mutation in a known 
hotspot region with a high allele frequency of 48.2%, being suggestive of germ-line 
mutation rather than being specific for JP.  Another ATM mutation with a high allele 
frequency (51%) was detected in a patient with positive family history (Nr. 10) also 
being suggestive of germ-line mutation. In this patient, there was no evidence of any 
tumor development within the four years follow-up period. In another patient (Nr. 3) 
there was a high variant allelic frequency (47.9%) in the MET gene (interpreted as 
conflicting pathogenicity clinical variant), also suggestive of germ line mutation, 
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however, this patient stayed free of disease after 17 years follow-up period. One 
further patient (Nr. 12) had FGFR3 mutations with a high frequency (50.9%, 
interpreted as benign/likely benign clinical variant) also being suggestive of germ-line 
mutation, however, this patient also remained free of disease in 9 years follow-up 
period.  In one patient with PIK3CA mutation with high allele-frequency (patient Nr: 
2), germline mutation was suspected, although this patient remained healthy in 10 
years follow-up. 
Relevant NGS results as well as clinical and patient history findings are summarized 
in Table 2.  
 
DISCUSSION 
In this study, we addressed the question whether genetic alterations occur in 
mammary juvenile papillomatosis and if those mutations could be correlated with 
findings associated to positive family history.  
We could show in our study, that PIK3CA, AKT1 and ATM variants together were 
present in 80% (8/10) of the analyzed JP patients. Several further mutations in genes 
such as MET, FGFR3, PTEN, ATM, NF1 and GNAS were found in individual 
patients. These results support existing literature data on mutational status of normal 
or proliferative breast tissue, however no data on somatic mutations in JP is available 
so far. 
Juvenile papillomatosis of the breast was probably first described by Kiaer in 1979 
and called extreme duct papillomas (13). Rosen reported this lesion as juvenile 
papillomatosis or Swiss cheese disease in 1980 due to its macroscopic resemblance 
to cheese from the Swiss Emmental region (1). Rosen defined several histological 
elements, which are diagnostic criteria for JP. Since its first description, JP has 
frequently been diagnosed in predominantly young and mostly in female patients, 
who clinically present with a palpable breast mass (1, 5). However, JP can also occur 
at higher age (report of 81 years old at first diagnosis) and in men (8, 14-16). A 
follow-up study by Rosen et al. in 1982 described that JP has a frequent association 
with positive family history for breast cancer in up to 26% (3). In following studies, a 
positive family history in patients with JP was reported in 26% to 58% of first- or 
second-degree relatives. Positive family history together with recurrent bilateral JP 
have thus been suggested as risk factor for developing invasive breast cancer (1-3, 
17) (Table 3).  Microscopically, epithelial atypia can be found in JP, however the 
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grade of epithelial atypia could not be shown to be associated with consecutive 
development of breast cancer (1-3, 17). 
The association between JP and concomitant breast cancer is very low; the first 
reports from 1979 through 1982 describe a very low occurrence of breast cancer (in 
the original reported cohorts it was secretory and lobular breast cancer subtype 
occurring concomitantly) in a very low subset of JP patients (1-3, 13). Since the last 
two decades several case reports with individual JP cases and only one large study 
on JP were published (8, 18-27). The number of cases is currently 352 including 
patients in this study (5, 8, 17, 26, 28-31). 36 reported patients (10.2%) developed 
breast carcinoma within the available follow-up period and 68 patients (19.3%) had a 
positive family history for breast cancer (second degree relatives in all cases). 
(summarized in Table 3).  
In our cohort of 13 JP cases, one of the patients developed contralateral invasive 
ductal breast cancer in the follow up period of 9 years. All other patients are free of 
breast disease in the available follow-up period. A positive family history for breast 
cancer (only second degree in all cases) in our series was 23%, which is similar to 
long existing demographic data of JP. 
 
As to imaging modalities, breast ultrasonography is the preferred method for 
diagnosis and follow-up of JP patients because of usually the young age at diagnosis 
(4). On  breast ultrasonography, JP usually presents as a hypoechoic mass with 
small cysts, in a subset of patients there is only an abnormal mammographic finding 
without corresponding palpable mass (4, 5). Magnetic resonance imaging findings of 
JP have been described as lobulated as well as well-bordered tubular-shaped 
masses with cystic and solid components (5). In our cohort, 7 of 13 patients 
underwent diagnostic ultrasonography prior to diagnostic biopsies / surgery. 
 
Not much is known about the association between JP and hereditary tumor 
syndromes. It is to assume that BRCA 1 / 2 mutational status does not apparently 
play a role in the evolution of JP. However, very limited patients with JP were 
diagnosed within the context of genetic aberrations in Neurofibromatosis (NF1), 
Cowden, Noonan or Proteus syndromes (5, 6, 32, 33). In one patient in this cohort, 
we detected PIK3CA mutation with high allele-frequency suggesting germline 
mutation, which has been described in patients with Cowden syndrome, Cowden-like 
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syndrome or in patients with overgrowth disorders in earlier papers (32, 34, 35). Our 
patient until the age of 45 in 10 years follow-up, showed no clinical findings 
suggestive of Cowden syndrome or overgrowth disorder. 
The genetic background of JP has not been explicitly addressed in any of the 
previous studies. According to our knowledge, this is the very first study to analyze 
hotspot and whole gene mutations in the florid epithelial proliferation of JP.  
We could show in our study that PIK3CA displays a reported hotspot mutation in 
about 50% of JP cases, accompanied by further hotspot (AKT1) or whole gene 
mutations (ATM) in the epithelial anatomical compartments. Several recent papers 
reported on hotspot mutations in the PIK3CA gene in breast lesions, including radial 
scar, adenomyoepithelioma, columnar cell lesions and further benign proliferative 
intraductal breast lesions (9, 11, 36-41).  Based on the limited recent literature data, 
PIK3CA and AKT1 mutations occur mutually exclusive in benign breast lesions, 
probably representing two ends of the same pathway (9-12, 36-41). In our study, this 
trend of mutually exclusive mutations of PIK3CA and AKT1 has been confirmed.  
Further mutations in benign breast lesions affecting the genes ATM, GNAS and MET 
have been reported in the literature and has been also confirmed in our study (40, 
42).  
 
In conclusion, the biological relevance of hotspot or whole gene mutations in benign 
breast lesions is not entirely clear and needs further explorative studies. On one 
hand, all mutations detected in JP patients in our cohort and in recent literature 
series in benign proliferative lesion, can occur in a high percentage of malignant and 
premalignant breast tumors as well (DCIS, invasive breast cancer) (9, 11, 36-41). 
Therefore, mutations on PIK3CA and AKT1 genes, as detected in our study are not 
specific for JP. Mutations in high allelic frequencies in individual patients, as detected 
in ATM, MET, FGFR3 genes, which may point to a possible germ-line mutation, 
would need interpretation in the whole context of the individual patient. As the 
surrounding uninvolved breast tissue was not included in our analysis, it remains an 
open question whether the mutations found in this study are either somatic mutations 
or germline mutations potentially also involving areas of the breast beyond the area 
with JP. In the absence of comparative data on control tissue not involved by JP, 
none of the described changes in our cohort can be specifically linked to JP. 
Mutations in 6 of 13 patients in this study may be germline (due to the high allelic 
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frequency) and in the remaining 7 patients could be somatic mutations and thus not 
specific to JP.  Based on the data presented in this study, no sufficient genetic 
association between benign lesions and positive family history for breast cancer in JP 
patients can be proven at the current time. 
 
ABBREVIATIONS 
JP: Juvenile papillomatosis  
NGS: Next generation sequencing 
DCIS: ductal carcinoma in situ 
BC: Breast cancer 
ER: Estrogen receptors 
NF1: Neurofibromatosis 1 
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LEGEND OF FIGURES 
Figure 1.  
Upper image: Gross appearance of Juvenile Papillomatosis. The breast tissue 
contains several cysts of different sizes intermingled with fibrotic areas. In some 
areas cysts are filled with intracystic liquid.  
Lower image: Low-power microscopic appearance of Juvenile Papillomatosis. On 
low-power view, there are several cysts surrounded by sclerosing adenosis and 
fibrosis. Many cysts contain intracystic mucus and epithelial proliferations and also 
apparent papillary fronds (Hematoxylin-eosin stain). 
 
 
Table 1. Clinical features of patients with JP 
Clinical characteristics (n=13)   No. of patients 
total13  
(%) 
Age (years) 
• Median 
• Range 
Race  
• White 
• Asian 
Menopausal status 
• Premenopausal 
Duration of follow-up (years) 
• Median 
• Range 
Imaging modality prior to excision 
• Ultrasound 
• Ultrasound and mammography 
• Mammography 
• Mammography and MRI 
• Ultrasound and MRI 
Imaging /clinical findings 
• Palpable mass 
• Unclear mammographic lesion 
Localization of JP tumor tissue 
• Left breast 
• Right breast 
• Bilateral  
Positive family history for breast cancer 
• First degree relative 
• Second degree relative 
 
38 
26-50  
 
11 
2 
 
13 (100%) 
 
9  
1-20 
 
3 
3 
1 
4 
1 
 
 
11 (85%) 
2 (15%) 
 
8 (60%) 
4 (30%) 
1 (7.6%) 
 
0  
3 (23%) 
Abbreviations: JP: juvenile papillomatosis, MRI: 
magnetic resonance imaging 
 
Patient 
number 
Age at 
diagnosis  
(years) 
Initial 
presentation 
Diagnostic 
workup 
leading to 
diagnosis  
Family 
history (FH) 
Duration of 
follow up/ 
development 
of breast 
cancer  
Genes Transcript Coding Variant 
Allele 
Frequency 
(%) 
Clinical Variant 
(ClinVar) 
1 25 
 
PM US, TE unknown unknown - - - - - 
2 35 
 
PM, initial 
presentation 
at age 7.   
US, FNA, 
TE 
Positive FH 
for breast 
cancer in 
aunt (2nd 
degree 
relative) 
10 years PIK3CA NM006218.3 c.3140A>G 39.4 Pathogenic/ 
Likely pathogenic 
3 47 PM, suspect 
MG 
TE Negative 17 years MET NM_001127500.2 c.3029C>T 47.9 Conflicting 
interpretations of 
pathogenicity 
4 46 PM MG, MRI, 
TE 
Unknown Unknown - - - - - 
5 48 MG US, FNA, 
TE 
Negative  Contralateral 
invasive 
ductal breast 
carcinoma 4 
years after 
diagnosis of 
JP; deceased 
due to 
metastatic 
disease 2 
years later  
ATM 
 
 
 
 
 
 
 
NF1 
NM_000051.3 
 
 
 
 
 
 
 
NM_001042492.2 
c.8395_8404del 
TTTCAGTGCC 
 
 
 
 
 
 
c.4006C>T 
48.2 
 
 
 
 
 
 
 
5.4 
Pathogenic/Likely 
pathogenic 
 
 
 
 
 
 
benign/likely 
benign 
6 50 PM TE Negative 15 years PTEN NM_000314.6 c.44_45delGA 9.7 Pathogenic/Likely 
pathogenic 
7 40 MG MG, FNA, 
TE 
Negative 11 years AKT1 NM_001014431.1 c..49G>A 41.4 Pathogenic/Likely 
pathogenic 
8 34 PM MG, MRI, 
TE 
Negative 5 years PIK3CA NM_006218.3 c.1624G>A 25 Pathogenic/Likely 
pathogenic 
9 40 PM; bloody 
secretion for 
several 
months  
MG, FNA, 
TE 
Positive, 
grandmother 
with 
mammary 
carcinoma 
(age at 
5 years AKT 1 
 
 
 
 
 
NM_001014431.1 
 
 
 
 
 
c.49G>A 
 
 
 
 
 
11 
 
 
 
 
 
Pathogenic/Likely 
pathogenic 
 
 
 
 
  
Table 2. 
Results of next generation sequencing (NGS) including association to clinical characteristics.  
Abbreviations: PM: palpable mass, MG: mammographic finding, US: ultrasound, FNA: fine-needle aspiration, TE: total excision,  
 
diagnosis 
and histology 
not known) 
 
GNAS   
 
NM_000516.5 
 
 
c.601C>T 
 
13.8 
 
Pathogenic/Likely 
pathogenic 
10 39 PM MG, FNA, 
TE 
Positive 
(cousin, 
grandmother) 
4 years PIK3CA 
 
 
ATM 
NM_006218.3 
 
 
NM_000051.3 
c.3140A>G 
 
 
c.9001_9002delAG 
32 
 
 
51 
Pathogenic/Likely 
pathogenic 
 
Pathogenic 
11 23 PM MG, MRI Negative 1 year - - - - - 
12 37 PM US, FNA, 
TE 
Negative 9 years PIK3CA 
 
 
FGFR3 
NM_006218.3 
 
 
NM_000142.4 
c.3140A>T 
 
 
c.1150T>C 
7.6 
 
 
50.9 
Pathogenic/Likely 
pathogenic 
 
Benign/Likely 
benign 
13 39 PM MG, MRI, 
TE 
Negative 6 years PIK3CA NM_006218.3 c.1633G>A 15.6 Pathogenic/Likely 
pathogenic 
Table 3. 
Original descriptions of juvenile papillomatosis 1979-1985 and summary of published papers since the original disease description in 1985. 
Abbreviations: JP (juvenile papillomatosis), MS (multiple sclerosis), BC (breast cancer), NF1 (neurofibromatosis type 1), NA (not available), FU (follow-up), PH (personal 
history), FH (family history), PM (palpable mass), LCIS (lobular carcinoma in situ), DCIS (ductal carcinoma in situ), JSC (juvenile secretory carcinoma), IDC (intraductal 
carcinoma), MDC (microinvasive ductal carcinoma), ILC (invasive lobular carcinoma), IDC (invasive ductal carcinoma).  
* The total number of cases in the four papers by Rosen is most likely 180. 
Year, Author, Reference 
number:  
N /gender Age in years (y) or 
months (mo): mean 
(range) 
Initial presentation (Nr. 
of cases) 
Breast cancer 
development Nr. of cases 
(onset in years after 
initial diagnosis); or 
synchronous other breast 
diseases 
Family history of breast 
carcinoma, number or 
patients (%) 
Associated genetic 
background/ Germline 
syndrome  
1979, Kiaer et al.,  
(ref. 13) 
 
3 / female  
 
14 y (11-17) PM (3) 2 (27; 11) 
 
NA  
 
 
1980, 1982, 1985, 1990, 
Rosen et al.,  
(ref. 1,2,3,24)* 
180 / female  
 
23 y (12-48)  PM (176) 
Pain (2) 
Nipple discharge (2)  
3 (synchronous LCIS)  
2 (associated IDC)  
2 (associated JSC) 
1 IDC (8) 
1 MDC (9) 
 
50 (28%)   
1985, Tokunaga N et al., 
(ref. 26) 
2 / female  13 y, 18 y PM 2 (associated JSC)  NA  
1986, Bazzocchi et al., 
(ref. 28) 
13 / female 25 y (15 - 42) PM (13) 2 (associated IDC )  4 (31%)  
1987, Ferguson et al.,  
(ref. 18) 
1 / female 6 y PM 1 (associated JSC) NA  
1995, Nonomura et al., 
(ref. 29) 
1 / female  12 y PM 1 (associated JSC) NA  
2000, Rice et al.,  
(ref. 15) 
2 / male  10.5 mo (7-14) PM (1) 
Nipple discharge and PM 
(1) 
NA NA  
 
2000, Munitiz et al.,  
(ref. 21)  
 
1 / male  33 y PM 1 (associated IDC) 
 
0   
2001, Hsieh et al.,  
(ref. 19) 
1/ female 9 y PM 0 0  
2003, Noccioli et al 
(ref. 22) 
1 /female 23 y PM 0 NA  
2005, Ohlinger et al.,  
(ref. 4) 
1/ female  16 y PM NA 0  
2005, Pacilli et al   
(ref. 6) 
1 /male 1 y PM 0 1 (100%) Noonan syndrome 
2007, El-Saify,  
(ref. 14) 
1/ female  81 y PM NA   NA   
2007, Tan et al  
(ref. 33) 
1 / female 9 mo PM NA NA Neurofibromatosis 1 
2011, Sanguinetti et al., 
(ref. 16) 
1 / male 17 y PM NA 0  
2013, Patterson et al.,  
(ref. 30) 
1 / female  21 y  PM  NA 0   
2014, Lad et al.,  
(ref. 17) 
1/ female 16 y PM NA 1 (100%)  
2014, Wang et al.,  
(ref. 27) 
1 / female  11 y PM 0  1 (100%)  
2015, Sedloev et al.,  
(ref. 7) 
1/ female  15 y PM 1 (associated DCIS) 0   
2018, Cheng et al.,  
(ref. 5) (including two 
published cases: 2017, 
Viswanathan K et al., (ref. 
8), 2016 Ozerdem et al. 
(ref 32)). 
120 / female  
1 / male 
 
34.1 y (13-77) PM: 94  
Imaging abnormality: 16 
- 1 (associated, ILC)  
- 4 (associated DCIS) 
- 1 (associated IDC)  
- 8 (associated LCIS)  
- 2 (IDC, 12 and 14 
months)   
6 (5%) - 1 case of  JP + Cowden 
disease 
- 1 case of  JP + Proteus 
syndrome and IDC  
2018, Olarinoye-Akorede 
SA et al., (ref. 23) 
1/ female 14 y  PM  NA 0  
2018, Kafadar et al.,  
(ref. 20) 
1/ female 11 y PM NA 0  
2019, Vandeweerd et al., 
(ref. 31) 
2 / female 
 
22, 23 y  PM  NA 2   
Patients described in this 
report 
13 / female 38 y (26-50) PM (11) 
Imaging abnormality (2) 
1 (4; IDC) 3 (23%)  
  
 
 
 
 Total number of cases 
(female/male) 
Median age (range) Initial presentation (%) Total number of 
carcinoma development 
(%):  
 
Total number of patients 
with positive family 
history of BC (%):  
 
 352 (344/6) 26 y (7mo – 81 y) 316 PM (89.7%) 
18 Imaging abnormality 
(5.1%) 
2 Pain (0.5%) 
2 Nipple discharge (0.5%) 
1 Nipple discharge and PM 
(0.25%) 
36/352 (10.2%)  
25 associated (7.1%) 
11 subsequent 
development (3.1%); 
mean: onset after 11 years 
68 (19.3 %)  

